Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24303162 | 0.82 | SLC6A4 (0.51) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL26328427 | 0.82 | GAA (0.52) | LMNASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26326729 | 0.78 | ADRB2 (0.48) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL758732 | 0.78 | SLC6A2 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL11490664 | 0.76 | SLC6A2 (0.46) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL26327813 | 0.76 | MEN1 (0.51) | LMNASLC6A4SLC6A3HTR1A | |
| SCHEMBL12498803 | 0.75 | HTT (0.47) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL11483225 | 0.75 | SLC6A4 (0.49) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL31074202 | 0.74 | HTR1A (0.44) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL3195289 | 0.74 | HTR1A (0.44) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ALDH1A1 4270/4885LMNA 3958/4885HTT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.